BACKGROUND: Advanced non-small cell lung cancer (NSCLC) patients who harbor anaplastic lymphoma kinase (ALK) rearrangement are sensitive to an ALK inhibitor (crizotinib), but not all ALK-positive patients benefit equally from crizotinib treatment. We analyze the impact of TP53 mutations on response to crizotinib in patients with ALK rearrangement NSCLC. METHODS: Sixty-six ALK rearrangement NSCLC patients receiving crizotinib were analyzed. 21 cases were detected successfully by the next generation sequencing validation FFPE before crizotinib. TP53 mutations were evaluated in 8 patients in relation to disease control rate (DCR), objective response rate (ORR), progression-free survival (PFS) and overall survival (OS). RESULTS: TP53 mutations were observed in 2 (25.00%), 1 (12.50%), 1 (12.50%) and 4 (50.00%) patients in exons 5, 6, 7 and 8, respectively. The majority of patients were male (75.00%, 6/8), less than 65 years old (62.50%, 5/8) and never smokers (75.00%, 6/8). ORR and DCR for crizotinib in the entire case series were 61.90% and 71.43%, respectively. Statistically significant difference was observed in terms of PFS and OS between TP53 gene wild group and mutation group patients (P=0.038, P=0.021, respectively). CONCLUSIONS: TP53 mutations reduce responsiveness to crizotinib and worsen prognosis in ALK rearrangement NSCLC patients.
BACKGROUND: Advanced non-small cell lung cancer (NSCLC) patients who harbor anaplastic lymphoma kinase (ALK) rearrangement are sensitive to an ALK inhibitor (crizotinib), but not all ALK-positive patients benefit equally from crizotinib treatment. We analyze the impact of TP53 mutations on response to crizotinib in patients with ALK rearrangement NSCLC. METHODS: Sixty-six ALK rearrangement NSCLC patients receiving crizotinib were analyzed. 21 cases were detected successfully by the next generation sequencing validation FFPE before crizotinib. TP53 mutations were evaluated in 8 patients in relation to disease control rate (DCR), objective response rate (ORR), progression-free survival (PFS) and overall survival (OS). RESULTS: TP53 mutations were observed in 2 (25.00%), 1 (12.50%), 1 (12.50%) and 4 (50.00%) patients in exons 5, 6, 7 and 8, respectively. The majority of patients were male (75.00%, 6/8), less than 65 years old (62.50%, 5/8) and never smokers (75.00%, 6/8). ORR and DCR for crizotinib in the entire case series were 61.90% and 71.43%, respectively. Statistically significant difference was observed in terms of PFS and OS between TP53 gene wild group and mutation group patients (P=0.038, P=0.021, respectively). CONCLUSIONS: TP53 mutations reduce responsiveness to crizotinib and worsen prognosis in ALK rearrangement NSCLC patients.
Authors: David S Ettinger; Douglas E Wood; Wallace Akerley; Lyudmila A Bazhenova; Hossein Borghaei; David Ross Camidge; Richard T Cheney; Lucian R Chirieac; Thomas A D'Amico; Todd L Demmy; Thomas J Dilling; M Chris Dobelbower; Ramaswamy Govindan; Frederic W Grannis; Leora Horn; Thierry M Jahan; Ritsuko Komaki; Lee M Krug; Rudy P Lackner; Michael Lanuti; Rogerio Lilenbaum; Jules Lin; Billy W Loo; Renato Martins; Gregory A Otterson; Jyoti D Patel; Katherine M Pisters; Karen Reckamp; Gregory J Riely; Eric Rohren; Steven E Schild; Theresa A Shapiro; Scott J Swanson; Kurt Tauer; Stephen C Yang; Kristina Gregory; Miranda Hughes Journal: J Natl Compr Canc Netw Date: 2015-05 Impact factor: 11.908
Authors: Xiaoli Ma; Gwénaël Le Teuff; Benjamin Lacas; Ming Sound Tsao; Stephen Graziano; Jean-Pierre Pignon; Jean-Yves Douillard; Thierry Le Chevalier; Lesley Seymour; Martin Filipits; Robert Pirker; Pasi A Jänne; Frances A Shepherd; Elisabeth Brambilla; Jean-Charles Soria; Pierre Hainaut Journal: J Thorac Oncol Date: 2016-02-17 Impact factor: 15.609
Authors: Robert C Doebele; Amanda B Pilling; Dara L Aisner; Tatiana G Kutateladze; Anh T Le; Andrew J Weickhardt; Kimi L Kondo; Derek J Linderman; Lynn E Heasley; Wilbur A Franklin; Marileila Varella-Garcia; D Ross Camidge Journal: Clin Cancer Res Date: 2012-01-10 Impact factor: 12.531
Authors: M Luana Poeta; Judith Manola; Meredith A Goldwasser; Arlene Forastiere; Nicole Benoit; Joseph A Califano; John A Ridge; Jarrard Goodwin; Daniel Kenady; John Saunders; William Westra; David Sidransky; Wayne M Koch Journal: N Engl J Med Date: 2007-12-20 Impact factor: 91.245
Authors: Malinda Itchins; Brandon Lau; Amanda L Hudson; Helen Westman; Cathy Yi Xia; Sarah A Hayes; Viive M Howell; Michael Rodriguez; Wendy A Cooper; Heng Wei; Michael Buckland; Bob T Li; Mark Li; Vivek Rathi; Stephen B Fox; Anthony J Gill; Stephen J Clarke; Michael J Boyer; Nick Pavlakis Journal: Oncologist Date: 2020-07-02
Authors: Shemra Rizzo; Sarah Waliany; Marius Rene Garmhausen; Navdeep Pal; Ruishan Liu; Zhi Huang; Nayan Chaudhary; Lisa Wang; Chris Harbron; Joel Neal; Ryan Copping; James Zou Journal: Nat Med Date: 2022-06-30 Impact factor: 87.241
Authors: Jingjing Li; Bin Zhang; Yu Zhang; Feng Xu; Zhenfa Zhang; Lin Shao; Chunhe Yan; Paola Ulivi; Marc G Denis; Petros Christopoulos; Vincent Thomas de Montpréville; Eric H Bernicker; Anthonie J van der Wekken; Changli Wang; Dongsheng Yue Journal: Transl Lung Cancer Res Date: 2021-03
Authors: Balázs Jóri; Markus Falk; Iris Hövel; Peggy Weist; Markus Tiemann; Lukas C Heukamp; Frank Griesinger Journal: Curr Oncol Date: 2022-09-16 Impact factor: 3.109